Neurochemical Research

, 31:361

Binding of 3H-WIN-35,428 and 125I-RTI-121 to Human Platelet Membranes

  • Donatella Marazziti
  • Stefano Baroni
  • Laura Fabbrini
  • Paola Italiani
  • Mario Catena
  • Bernardo Dell’Osso
  • Laura Betti
  • Gino Giannaccini
  • Antonio Lucacchini
  • Giovanni B. Cassano


The dopamine transporter (DAT) is a protein regulating dopamine concentration in the synaptic cleft through the re-uptake mechanism. The DAT is the main target of psychostimulants and seems to play a pivotal role in neuronal degeneration and different neuropsychiatric disorders involving the dopamine system. Exhaustive research, however, regarding the presence of this protein in human platelets is still inconclusive, although it is thought that it might provide a peripheral tool to serve as a mean of exploring the same structure present in the brain. Therefore, we assessed some binding assays in platelets derived from healthy human subjects by means of 3H-WIN 35,428, a compound which is considered a selective ligand for the labelling of this protein, and by means of 125I-RTI-121, another compound with high specificity for DAT. The results showed that the binding of 3H-WIN-35,428 was too low to enable the detection of any structure; the binding of 125I-RTI-121, on the other hand, revealed the presence of two binding sites with pharmacological profiles similar to that of the serotonin transporter (SERT). In conclusions, therefore, platelets would not seem to be a useful model for exploring the DAT, given the prevalence therein of the SERT and the difficulty of labelling the DAT with the currently available ligands.


Dopamine Transporter (DAT) Serotonin Transporter (SERT) human platelets 3H-WIN 35,428 125I-RTI-121 


  1. 1.
    Hoffman BJ, Hansson SR, Mezey E, Palkovits M (1998) Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol 19(3):187–231CrossRefPubMedGoogle Scholar
  2. 2.
    Thibaut F, Vaugeois JM, Petit M (1995) The dopamine transporter: characterization and physiopathologic implications. Encephale 21(6):445–451PubMedGoogle Scholar
  3. 3.
    Amara SG, Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Ann Rev Neurosci 16:73–93CrossRefPubMedGoogle Scholar
  4. 4.
    Giros B, Mestikawy SE, Bertrand L, Caron MG (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS 295:149–154CrossRefGoogle Scholar
  5. 5.
    Little KY, Carroll FI, Cassin BJ (1995) Characterization and localization of [125I]RTI-121 binding sites in human striatum and medial temporal lobe. J Pharmacol Exp Ther 274(3):1473–1483PubMedGoogle Scholar
  6. 6.
    Staley JK, Boja JW, Carroll FI, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Mash DC (1995) Mapping dopamine transporters in the human brain with novel selective cocaine analog [125I]RTI-121. Synapse 21(4):364–372CrossRefPubMedGoogle Scholar
  7. 7.
    Boja JW, Carroll FI, Vaughan RA, Kopajtic T, Kuhar MJ (1998) Multiple binding sites for [125I]RTI-121 and other cocaine analogs in rat frontal cerebral cortex. Synapse 30(1):9–17CrossRefPubMedGoogle Scholar
  8. 8.
    Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219–1223PubMedCrossRefGoogle Scholar
  9. 9.
    Reith ME, De Costa B, Rice KC, Jacobson AE (1992) Evidence for mutually exclusive binding of cocaine, BTCP, GBR 12935, and dopamine to the dopamine transporter. Eur J Pharmacol. 227(4):417–425CrossRefPubMedGoogle Scholar
  10. 10.
    Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependend and cocaine-sensitive mechanism. Proc Natl Acad Sci USA. 97:6850–6855CrossRefPubMedGoogle Scholar
  11. 11.
    Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE (2001) Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci 21:1413–1419PubMedGoogle Scholar
  12. 12.
    Seiden LS, Sabol KE (1995) Neurotoxicity of methamphetamine-related drugs and cocaine. In: Chang LW, Dyer RS (eds) Handbook of neurotoxicology, Marcel Dekker, New York. pp 359–366Google Scholar
  13. 13.
    Tatsumi M, Groshian K, Blakely RD, Richelson E (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249–258CrossRefPubMedGoogle Scholar
  14. 14.
    Seeman P, Niznik HB (1990) Dopamine recetors and transporters in Parkinson’s disease an schizophrenia. FASEB J 4:2737–2744PubMedGoogle Scholar
  15. 15.
    Rabey JM, Lerner A, Sigal M, Graff E, Oberman Z (1992) [3H]dopamine uptake by platelet storage granules in schizophrenia. Life Sci 50(1):65–72CrossRefPubMedGoogle Scholar
  16. 16.
    Kugaya A, Fujita M, Innis RB (2000) Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders. Ann Nucl Med 14:1–9PubMedCrossRefGoogle Scholar
  17. 17.
    Volkow ND, Fowler JS, Wang GJ (1994) Decreased dopamine transporter with age in healthy human subject. Ann Neurol 32:237–239CrossRefGoogle Scholar
  18. 18.
    Romero-Ramos M, Rodriguez-Gomez JA, Venero JL, Cano J, Machado A (1997) Chronic inhibition of the high affinity dopamine uptake system increases oxidative damage to proteins in the aged rat substantia nigra. Fri Radical Biol Med 23:1–7CrossRefGoogle Scholar
  19. 19.
    Stahl SM (1977) The human platelet. A diagnostic and research tool for the study of biogenic amines in psychiatric and neurologic disorders. Arch Gen Psychiatry 34(5):509–516PubMedGoogle Scholar
  20. 20.
    Da Prada M, Cesura AM, Launay JM, Richards JG (1988) Platelets as a model for neurons?. Experientia15 44(2):115–126CrossRefGoogle Scholar
  21. 21.
    Lesch KP, Wolozin BL, Murphy DL, Riederer A (1993) Primary structure of the human platelet serotonin uptake: identity with the brain serotonin transporter. J Neurochem 60:2319–2322PubMedCrossRefGoogle Scholar
  22. 22.
    Marazziti D, Rossi A, Gemignani A, Giannaccini G, Pfanner C, Milanfranchi A, Presta S, Lucacchini A, Cassano GB (1996) Decreased 3H-paroxetine binding in obsessive–compulsive patients. Neuropsychobiology 34:84–187Google Scholar
  23. 23.
    Marazziti D, Rossi A, Dell’Osso L, Palego L, Placidi G.F, Giannaccini G, Lucacchini A, Cassano GB (1999) Decreased platelet 3H-paroxetine binding in untreated panic disorder patients. Life Sci 65:2735–2742CrossRefPubMedGoogle Scholar
  24. 24.
    Dean B, McAdam AJ, Sundram S, Pavey G, Harrison LC, Copolov DL (1992) Identification of a dopamine-binding protein on the membrane of the human platelets. Biochem J 287:45–50PubMedGoogle Scholar
  25. 25.
    Gordon I, Weizman R, Rehavi M (1994) 3H-GBR 12935 binding to human platelet membranes is sensitive to piperazine derivatives but not to dopamine uptake inhibitors. Life Sci 55(3):89–99CrossRefGoogle Scholar
  26. 26.
    Xu C, Reith EA (1997) WIN 35,428 and mazindol are mutually exclusive in binding to the cloned human dopamine transporter. Pharmacol Exp Therap 282:920–927Google Scholar
  27. 27.
    Boja JW, Cadet JL, Kopajtic TA, Lever J, Seltzman HH, Wyrick CD, Lewin AH, Abraham P, Carroll FI (1995) Selective labeling of the dopamine transporter by the high-affinity ligand 3 beta-(4-[125I]iodophenyl)tropane-2 beta-carboxylic acid isopropyl ester. Mol Pharmacol 47(4):779–786PubMedGoogle Scholar
  28. 28.
    Lever JR, Scheffel U, Stathis M, Seltzman HH, Wyrick CD, Abraham P, Parham K, Thomas BF, Boja JW, Kuhar MJ, Carroll FI (1996) Synthesis and in vivo studies of a selective ligand for the dopamine transporter: 3 beta-(4-[125I]iodophenyl) tropan-2 beta-carboxylic acid isopropyl ester ([125I]RTI-121). Nucl Med Biol 23(3):277–284CrossRefPubMedGoogle Scholar
  29. 29.
    Peterson GL, (1977) A simplification of the protein assay method that is more generally applicable. Analyt Biochem 83:346–356CrossRefPubMedGoogle Scholar
  30. 30.
    Mc Pherson, GA (1985) A collection of radioligand binding analysis programs. In: Lowry, Kinetic. Ebda, Ligand. Biosoft, Cambridge Google Scholar
  31. 31.
    Chen NH, Ding JH, Wang YL (1997) Binding of [125I]3B-(iodophenyl)tropane-2b-carboxylic acid isopropyl ester to the dopamine transporter at a physiologically relevant temperature: mutually exclusive binding and different ionic requirement for various uptake blockers and substrates. Synapse 25:155–162CrossRefPubMedGoogle Scholar
  32. 32.
    Lingjaerde O, (1995) Dopamine uptake in platelets. Biol Psychiatry 38(6):416–417CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Donatella Marazziti
    • 1
    • 2
  • Stefano Baroni
    • 1
  • Laura Fabbrini
    • 1
  • Paola Italiani
    • 1
  • Mario Catena
    • 1
  • Bernardo Dell’Osso
    • 1
  • Laura Betti
    • 1
  • Gino Giannaccini
    • 1
  • Antonio Lucacchini
    • 1
  • Giovanni B. Cassano
    • 1
  1. 1.Dipartimento di Psichiatria, Neurobiologia, Farmacologia e BiotecnologieUniversity of PisaPisaItaly
  2. 2.Dipartimento di Psichiatria, Neurobiologia, Farmacologia e BiotecnologieUniversity of PisaPisaItaly

Personalised recommendations